Výsledky vyhledávání - "S. P. Balcerzak"

Akademický článek

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas

Autor: M. von Mehren, S. P. Balcerzak, A. S. Kraft, J. H. Edmonson, S. H. Okuno, M. Davey, S. Mclaughlin, M. T. Beard, A. Rogatko

Publikováno v: Sarcoma, Vol 8, Iss 4, Pp 107-111 (2004)

Patients:Soft tissue sarcomas are uncommon malignancies with few therapeutic options for recurrent or metastatic disease. Dolastatin-10 (Dol-10) is a pentapeptide anti-microtubule agent that binds to tubulin sites distinct from vinca alkaloids. Based

Externí odkaz: https://doaj.org/article/eaa4b43d1e9c4b16a8543458dd5dbe3a

Zobrazit plný text záznamu

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas

Autor: M, von Mehren, S P, Balcerzak, A S, Kraft, J H, Edmonson, S H, Okuno, M, Davey, S, McLaughlin, M T, Beard, A, Rogatko

Publikováno v: Sarcoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::739cccd8b6998f00037ab228e9c70a66
https://pubmed.ncbi.nlm.nih.gov/18521404

Zobrazit plný text záznamu

Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study

Autor: S K, Williamson, D, Lew, G J, Miller, S P, Balcerzak, L H, Baker, E D, Crawford

Publikováno v: Cancer. 88(5)

A previous Southwest Oncology Group study demonstrated a 30% response rate with the combination of cisplatin and mitotane in the treatment of patients with metastatic adrenocortical carcinoma. Several case reports suggested that the combination of et

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4360ecd4acf95b01152137fec0e9e527
https://pubmed.ncbi.nlm.nih.gov/10699907

Zobrazit plný text záznamu

Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study

Autor: J A, Kish, J K, Benedetti, S P, Balcerzak, R W, Veith, R, Davis, T W, Pollock, D E, Schuller, J F, Ensley

Publikováno v: The cancer journal from Scientific American. 5(5)

Appropriate adjuvant chemotherapy for resected head and neck cancer patients has yet to be defined. Multiple trials have noted trends toward improved disease-free survival and local control. The Southwest Oncology Group undertook a feasibility trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::77f3096cd776ca482773b01e844e5e43
https://pubmed.ncbi.nlm.nih.gov/10526672

Zobrazit plný text záznamu

Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial

Autor: P J, Hesketh, J J, Crowley, H A, Burris, S K, Williamson, S P, Balcerzak, D, Peereboom, J W, Goodwin, H M, Gross, D F, Moore, R B, Livingston, D R, Gandara

Publikováno v: The cancer journal from Scientific American. 5(4)

This phase II multi-institutional trial of the Southwest Oncology Group was designed to evaluate the efficacy and toxicity of docetaxel in chemotherapy-naive patients with extensive-stage small cell lung cancer.Forty-seven patients with extensive-sta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::200f849f9f9e253f094fdf1f6901ece7
https://pubmed.ncbi.nlm.nih.gov/10439170

Zobrazit plný text záznamu

A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study

Autor: V K, Sondak, P Y, Liu, L E, Flaherty, W S, Fletcher, P, Periman, D R, Gandara, S A, Taylor, S P, Balcerzak, F L, Meyskens

Publikováno v: The cancer journal from Scientific American. 5(1)

Interferon alfa has modest but definite activity in the treatment of metastatic melanoma and is the only agent currently available for adjuvant therapy of high-risk resected disease. A variety of retinoic acid derivatives have been shown to be synerg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::83bdfc0c7ab5074e6393eee6e62c5930
https://pubmed.ncbi.nlm.nih.gov/10188060

Zobrazit plný text záznamu

Differential diagnosis of hereditary hemochromatosis from other liver disorders by genetic analysis: gene mutation analysis of patients previously diagnosed with hemochromatosis by liver biopsy

Autor: C, Bartolo, P E, McAndrew, R C, Sosolik, K A, Cawley, S P, Balcerzak, J T, Brandt, T W, Prior

Publikováno v: Archives of pathologylaboratory medicine. 122(7)

Hereditary hemochromatosis, a common autosomal recessive trait caused by mutations in the HLA-H gene, is often diagnosed by the pathologist at the time of histologic examination. Unfortunately, histologic parameters alone do not differentiate between

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1d4b24b22d444e7c28a6536520ebd688
https://pubmed.ncbi.nlm.nih.gov/9674544

Zobrazit plný text záznamu

A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma

Autor: K, Antman, J, Crowley, S P, Balcerzak, R A, Kempf, R B, Weiss, G H, Clamon, L H, Baker

Publikováno v: Cancer. 82(7)

Ewing's sarcomas, osteosarcomas, and rhabdomyosarcomas are significantly more responsive to chemotherapy than other sarcomas. Adjuvant chemotherapy is used routinely based on data from randomized trials. Although a percentage of children with locally

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::487c04d5f81705cfdc6508f21705a9a1
https://pubmed.ncbi.nlm.nih.gov/9529020

Zobrazit plný text záznamu

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Autor: J K, Weick, K J, Kopecky, F R, Appelbaum, D R, Head, L L, Kingsbury, S P, Balcerzak, J N, Bickers, H E, Hynes, J L, Welborn, S R, Simon, M, Grever

Publikováno v: Blood. 88(8)

Interest in high-dose cytarabine (HDAC) for both induction and postremission therapy for acute myeloid leukemia (AML) prompted the Southwest Oncology Group (SWOG) to initiate a randomized trial comparing HDAC with standard-dose cytarabine (SDAC) for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9732cd51d9ba54877fe386e4c01c7ffb
https://pubmed.ncbi.nlm.nih.gov/8874180

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání